Email this article Randomized comparison of vaginal and sublingual misoprostol with mifepristone priming in termination of second trimester pregnancy
Abstract
Background: Sublingual Misoprostol 200 ug 4 hrly is as effective or less effective than vaginal Misoprostol 200ug 4hrly with 200mg oral Mifepristone in termination of second trimester pregnancy.
To compare effectiveness, side-effects, and patient satisfaction of sublingual vs vaginal misoprostol administration.
Methods: It was prospective randomized open label study. 60 women 13-20 weeks of gestation with a valid legal indication for termination of pregnancy as per MTP act in INDIA were enrolled for study, randomly divided into Group A- Sublingual (n=30) group B-Vaginal (n=30). For group A, 200 mg of Mifepristone was given, 48h later Misoprostol 200 µg was given sublingually 4hrly up to a maximum of 5 doses. If abortion does not occur, the pregnancy was terminated with vaginal misoprostol, in group A. Same procedure repeated in group B. If abortion fails to occur after 5 doses, then second course of vaginal misoprostol was given in group B. Failure of procedure was defined as failed expulsion of foetus at 48 hrs.
Results: Mean induction-abortion interval in vaginal group was 12.8±4.38h and 11.47±4.42h in sublingual group was comparable with insignificant p value (p=0.136). All the side effects were comparable in both groups. The overall success rate was 93.3% in the sublingual group while it was 100% in the vaginal group.
Conclusion: Vaginal misoprostol with oral mifepristone priming in second -trimester medical abortion has a shorter time to pregnancy termination compared with a sublingual regimen. However, both the routes are equally effective for induction of abortion.
Keywords
Full Text:
PDFReferences
Dhillon BS, Chandhiok N, Kambo I, Saxena NC. Induced abortion and concurrent adoption of contraception in the rural areas of India (an ICMR task force study). Indian J Med Sci. 2004;58:478-84.
Sedgh G, Henshaw S, Singh S, Ahman E, Shah IH. Induced abortion: Estimated rates and trends worldwide. The Lancet. 2007 Oct 13;370(9595):1338-45.
Padubidri VG, Daftary SN. Shaw’s textbook of gynaecology (13th ed), New Delhi, Elsevier. 2004:241.
Tejal P, Bakul A. 17-year review of voluntary termination of pregnancy (MTP). J Obstetr Gynecol India. 2006;56(6):522-8.
Tejal P, Bakul L. A 17-year review of voluntary termination of pregnancy (MTP). J Obstetr Gynecol India. 2006;56(6);522-8.
World Health Organization. Medical methods for termination of pregnancy, World Health Organization, Geneva 1997,871. Available at: extranet.who.int.
Cabrera Y, Fernández‐Guisasola J, Lobo P, Gamir S, Alvarez J. Comparison of sublingual versus vaginal misoprostol for second trimester pregnancy termination, A meta-analysis. Aust N Z Y Obstet-Gynecol. 2011;51(2),158-65.
Darney PD, Sweet RL. Routine intraoperative ultrasonography for second trimester abortion reduces incidence of uterine perforation. J Ultrasound Med. 1989;8(2):71-5.
Ngai SW, Tang OS, Chan YM, Ho PC. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. Human Reproduct. 2000 May 1;15(5):1159-62.
Tang OS, Ho PC. Pilot study on the use of sublingual misoprostol for medical abortion. Contraception. 2001;64(5):315-7.
Autry AM, Hayes EC, Jacobson GF, Kirby RS. A comparison of medical induction and dilation and evacuation for second-trimester abortion. Am J Obstet Gynecol. 2002;187(2):393-7.
Bartley J, Baird DT. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG 2002;109(11):1290-4.
Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contracept. 2004;69(1):51-8
Urquhart DR, Bahzad C, Templeton AA. Efficacy of the antiprogestin mifepristone (RU 486) prior to prostaglandin termination of pregnancy. Human Reproduct. 1989 Feb 1;4(2):202-3.
Urquhart DR, Templeton AA. The use of mifepristone prior to prostaglandin-induced mid-trimester abortion. Human Reproduct. 1990 Oct 1;5(7):883-6.
Tanha FD, Golgachi T, Niroomand N, Ghajarzadeh M, Nasr R. Sublingual versus vaginal misoprostol for second trimester termination: a randomized clinical trial. Archiv Gynecolo Obstetr. 2013 Jan 1;287(1):65-9.
Tanha FD, Golgachi T, Niroomand N, Gajaradeh M, Nasr R. Sublingual versus vaginal misoprostol for second trimester termination; a randomized clinical trial. Arch Gynecol obstet. 2013;287(1);659.
Fogsi Icog Good Clinical Practice Recommendation Medical Termination of Pregnancy: J Obstetr Gynecol of India. 2011;91.
World Health Organisation; Safe abortion: Technical and Policy guidance for health systems 2nd ed. Geneva: 2012. Available at: apps.who.int.
Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF, Kapp N. Medical methods for Mid-trimester termination of pregnancy. Cochrane Database Syst Rev. 2011;19(1):CD005216.
Dickinson JE, Brownell P, McGinnis K, Nathan E. Mifepristone and second trimester pregnancy termination for fetal abnormality in Western Australia: worth the effort. Aust NZ J Obstet Gynaecol. 2010;50(1):60-4.
Milani F, Sharami SH, Arjmandi S. Comparison of sublingual and vaginal misoprostol for second-trimester pregnancy terminations. J Family Reprod Health. 2014 Mar;8(1):41-4.
Bartusevicius A, Barcaite E, Nadisauskiene R. Oral, vaginal and sublingual misoprostol for induction of labor. Int J of Gynecol Obstet. 2005; 91:2-9.
el-Refaey H, Templeton A. Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomized comparison between two misoprostol regimens. Hum Reprod. 1995;10(2):475-8.
Ashok PW, Templeton A. Nonsurgical mid‐trimester termination of pregnancy: a review of 500 consecutive cases. BJOG: Intern J Obst Gynaecol. 1999 Jul;106(7):706-10.
Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contracept. 2004 Jan 1;69(1):51-8.
Dickinson JE, Brownell P, McGinnis K, Nathan E. Mifepristone and second trimester pregnancy termination for fetal abnormality in Western Australia: worth the effort. Aust NZ J Obstet Gynaecol. 2010;50(1):60-4.
Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo‐controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Human Reprod. 2003 Nov 1;18(11):2315-8.
Hamoda H, Ashok PW, Dow J, Flett GM, Templeton A. A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. Contracept. 2003;68(5):335-8.
Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Human Reproduc. 2002;17(2):332-6.
Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG. 2004;111(9),1001-05.
